EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS

Varela-Rey I 1*, González-Barcia M 1, García-Quintanilla L 1, Castro-Balado A 1, Busto-Iglesias M 1, Zarra-Ferro I 1, Fernández-Ferreiro A 1

1 Clinical University Hospital of Santiago de Compostela, Hospital Pharmacy Department, Santiago de Compostela, Galicia, Spain
*iria.varela.rey@sergas.es

BACKGROUND AND IMPORTANCE:
Tacrolimus is a widely used immunosuppressant in many ophthalmic diseases. Its mechanism of action is the inhibition of calcineurin phosphatases, which inhibits the first phase of T-cell activation, which leads to a decrease in inflammatory activity. In Spain, no eye drops are commercialized, so its formulation as a pharmaceutical compounding in Hospital Pharmacy services is necessary.

AIM AND OBJECTIVES:
To evaluate the use, adherence and tolerance of 0.03% tacrolimus eye drops pharmaceutical compounding.

MATERIALS AND METHODS:
- Retrospective observational study.
- Patients treated with 0.03% tacrolimus eye drops.

Recording:
- Demographic data: sex and age.
- Clinical data: pathology, duration, adherence and tolerance.

Adherence was measured by registration of dispensations, classifying as the highest level of adherence has no delay in dispensing, as well as by follow-up controls by Ophthalmology service.

RESULTS:

Demographic data:
- 54 patients
- 57.14% men
- 32.70±21.8 years

Mean duration:
- 1.8±1.0 years.

Uses of 0.03% tacrolimus eye drops
- 61.80% for atopic or vernal keratoconjunctivitis.
- 12.73% for Immune-mediated diseases
- 5.45% for Dry eye
- 20.00% for Graft rejections
- 0% for Inflammation of unknown

Tolerance of 0.03% tacrolimus eye drops
- 61.11% Good tolerance
- 24.07% Itching
- 3.70% Adverse effects

CONCLUSION AND RELEVANCE:
Tacrolimus eye drops are used primarily for the treatment of vernal or atopic keratoconjunctivitis. Adherence was generally correct and the formulation has been well tolerated by most of the patients.